Another potential biomarker is CK-18, whose fragments are released into the circulation as a result of hepatocyte death; the determination of CK-18 has shown promising results for the discrimination of the SS from NASH, but again, it needs further validation in larger patient cohorts [36]. The gene discussed is KRT18; the disease is metabolic dysfunction-associated steatohepatitis.